11¿ù 6ÀÏ (±Ý)
09:45 10:00 Àλ縻 ´ëÇÑÇ÷¾×ÇÐȸ ȸ    Àå À±¼º¼ö
ÀÌ»çÀå ÀÌÁ¦È¯
10:00 12:00 ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
Session I: Microenvironment and immune landscape in multiple myeloma ÁÂÀå : ÀÌÁ¦Áß
10:00 10:30 Role of microenvironment in the pathogenesis of multiple myeloma
VOD ´Ù½Ãº¸±â
±è¸í½Å(°¡Å縯ÀÇ´ë)
10:30 11:00 Immune landscape in multiple myeloma
VOD ´Ù½Ãº¸±â
°í¿µÀÏ(¼­¿ïÀÇ´ë)
Session II: Treatment of transplant-eligible multiple myeloma ÁÂÀå : ¹Îâ±â
11:00 11:30 Evolving therapeutic options in the induction treatment for transplant-eligible multiple myeloma
VOD ´Ù½Ãº¸±â
Á¶Àçö(¿ï»êÀÇ´ë)
11:30 12:00 Role of autologous stem cell transplant in elderly patients and post-transplant therapeutic options
VOD ´Ù½Ãº¸±â
¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ)
12:00 13:00 Á¡½É
13:00 15:00 °ñ¼öÁõ½ÄÁ¾¾ç¿¬±¸È¸
13:00 13:30 Diagnostic workflow for erythrocytosis and thrombocytosis
VOD ´Ù½Ãº¸±â
¼ºÈ­Á¤(°í·ÁÀÇ´ë)
13:30 14:00 Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN
VOD ´Ù½Ãº¸±â
À̼ºÀº(°¡Å縯ÀÇ´ë)
14:00 14:30 Post-ET/PV Myelofibrosis vs Primary Myelofibrosis
VOD ´Ù½Ãº¸±â
±è¹Î°æ(¿µ³²ÀÇ´ë)
14:30 15:00 A significance of hydroxyurea resistance in MPN patients
VOD ´Ù½Ãº¸±â
±è¼º¿ë(°Ç±¹ÀÇ´ë)
11:30 12:00 The role of interferon in MPNs
VOD ´Ù½Ãº¸±â
À±¼®À±(¼øõÇâÀÇ´ë)
15:00 15:15 ÈÞ½Ä
15:15 18:15 ¼ºÀÎ/¼Ò¾ÆALL ¿¬±¸È¸
Important but unsolved issues in adult ALL ÁÂÀå : µµ¿µ·Ï
15:15 15:45 Molecular genetics in adult B-cell ALL
VOD ´Ù½Ãº¸±â
Á¤¼ºÈÆ(Àü³²ÀÇ´ë)
15:45 16:15 Molecular genetics in adult T-cell ALL
VOD ´Ù½Ãº¸±â
À±ÀçÈ£(°¡Å縯ÀÇ´ë)
16:15 16:45 Treatment of relapsed/refractory T-ALL in adult patients
VOD ´Ù½Ãº¸±â
¹éµ¿¿ø(°æºÏÀÇ´ë)
16:45 17:00 NGS MRD ±â¹Ý ¼Ò¾Æû¼Ò³â ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´ ´Ù±â°ü ¿¬±¸°èȹ
VOD ´Ù½Ãº¸±â
ÃÖÁ¤À±(¼­¿ïÀÇ´ë)
17:00 17:15 NGS MRD ºÐ¼®¹æ¹ý 1
VOD ´Ù½Ãº¸±â
±è¸í½Å(°¡Å縯ÀÇ´ë)
17:15 17:30 NGS MRD ºÐ¼®¹æ¹ý 2
VOD ´Ù½Ãº¸±â
¼º¹®¿ì(¼­¿ïÀÇ´ë)
17:30 17:45 NGS MRD ºÐ¼®¹æ¹ý 3
VOD ´Ù½Ãº¸±â
À̽ÂÅÂ(¿¬¼¼ÀÇ´ë)
17:45 18:15 ÆгÎÅäÀÇ
VOD ´Ù½Ãº¸±â
11¿ù 07ÀÏ (Åä¿äÀÏ)
09:00 10:00 ÆòÀÇ¿øȸ(¿Â¶óÀÎ)
10:00 12:00 AML/MDS¿¬±¸È¸
Gap & perspective of targeted therapies for AML/MDS ÁÂÀå : ±èÇüÁØ/Á¤ÁØ¿ø
10:00 10:30 FLT3 inhibitors & Bcl-2 inhibitor for adult AML
VOD ´Ù½Ãº¸±â
Á¤ÁØ¿ø(¿¬¼¼ÀÇ´ë)
10:30 11:00 Targeting gene mutations and epigenetic regulators for pediatric AML
VOD ´Ù½Ãº¸±â
À¯°ÇÈñ(¼º±Õ°üÀÇ´ë)
11:00 11:30 What comes next to HMA for MDS?
VOD ´Ù½Ãº¸±â
±èÀ¯Áø(°¡Å縯ÀÇ´ë)
11:30 12:00 Multi parameterflow cytometry for AML/MDS
VOD ´Ù½Ãº¸±â
¼ÛÀç¿ì(¿¬¼¼ÀÇ´ë)
11¿ù 6ÀÏ (±Ý)
09:45 10:00 Àλ縻 ´ëÇÑÇ÷¾×ÇÐȸ ȸ    Àå À±¼º¼ö
ÀÌ»çÀå ÀÌÁ¦È¯
10:00 12:00 ÀûÇ÷±¸Áúȯ¿¬±¸È¸
10:00 10:05 (10:00-10:05) À§¿øÀå Àλ縻 & ¼Ò°³ ÀûÇ÷±¸Áúȯ¿¬±¸È¸ À§¿øÀå ÃÖÇü¼ö
Session I ÁÂÀå : ÃÖÇü¼ö/Á¤Çý¸²
10:05 10:20 ¼±Ãµ¿ëÇ÷ºóÇ÷ÀÇ epidemiology study °æÇè°ú °³¼±¹æÇâ
VOD ´Ù½Ãº¸±â
½É¿¹Áö(°è¸íÀÇ´ë)
10:20 10:35 ¼±Ãµ¿ëÇ÷ºóÇ÷ ȤÀº ¼±ÃµºóÇ÷ÀÇ ±¹³» Registry ±¸ÃàÀÇ Çʿ伺
VOD ´Ù½Ãº¸±â
ÃÖÈñ¿ø(µ¿¾ÆÀÇ´ë)
Session II ÁÂÀå : ÇÑÁø¿µ
10:35 11:05 NGS¸¦ È°¿ëÇÑ ºóÇ÷ÀÇ Áø´Ü
VOD ´Ù½Ãº¸±â
Ȳ»ó¹Ì(¼­¿ïÀÇ´ë)
11:05 11:10 Áú¹® & discussion
Session III ÁÂÀå : ÇÏÁ¤¿Á/±èÀÎÈ£
11:10 11:30 Autoimmune hemolytic anemia ¼ºÀο¡¼­ÀÇ °æÇè
VOD ´Ù½Ãº¸±â
¼ÛÀÍÂù(Ãæ³²ÀÇ´ë)
11:30 11:50 Autoimmune hemolytic anemia ¼Ò¾Æ¿¡¼­ÀÇ °æÇè
VOD ´Ù½Ãº¸±â
ÁÖÈñ¿µ(¼º±Õ°üÀÇ´ë)
11:50 12:00 Áú¹® & discussion
12:00 13:00 Á¡½É
13:00 15:00 Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸
13:00 13:05 Opening remarks Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ À§¿øÀå ÀÓÈ£ÁØ
Session I: Recent updates in LCH ÁÂÀå : ¼­Á¾Áø
13:05 13:25 Updates on target agents of LCH
VOD ´Ù½Ãº¸±â
Çѽ¹Î(¿¬¼¼ÀÇ´ë)
13:25 13:45 CNS LCH
VOD ´Ù½Ãº¸±â
È«°æÅÃ(¼­¿ïÀÇ´ë)
Session II: Recent updates in HLH ÁÂÀå : À¯Ã¶ÁÖ
13:45 14:05 Updates on target agents of HLH
VOD ´Ù½Ãº¸±â
ÀÌÀç¿í(°¡Å縯ÀÇ´ë)
14:05 14:25 Understanding of MAS
VOD ´Ù½Ãº¸±â
ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë)
14:25 14:45 Real world experience for haploidentical HSCT in HLH
VOD ´Ù½Ãº¸±â
ÀÓÈ£ÁØ(¿ï»êÀÇ´ë)
14:45 14:50 Closing remarks Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ À§¿øÀå ÀÓÈ£ÁØ
15:00 15:15 ÈÞ½Ä
15:15 18:15 Ç÷ÀüÁöÇ÷¿¬±¸È¸
15:15 15:20 Opening remarks
Session I: : Pregnancy ÁÂÀå : ¿Àµµ¿¬/±èÁø¼®
15:20 15:40 Obstetric issues in bleeding disorders
VOD ´Ù½Ãº¸±â
À¯ÄèÇÑ(°¡ÃµÀÇ´ë)
15:40 16:00 Obstetric issues in thrombophilic conditions (IVF µî Æ÷ÇÔ)
VOD ´Ù½Ãº¸±â
¾È¼­¿¬(Àü³²ÀÇ´ë)
16:00 16:10 Session Q&A
VOD ´Ù½Ãº¸±â
16:10 16:20 ÈÞ½Ä
Session II: Bleeding disorders ÁÂÀå : ¹æ¼ö¹Ì/±è¼ºÇö
16:20 16:40 Congenital bleeding disorder
VOD ´Ù½Ãº¸±â
ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë)
16:40 17:00 Acquired hemophilia
VOD ´Ù½Ãº¸±â
Çö½Å¿µ(¿¬¼¼ÀÇ´ë)
17:00 17:10 Session Q&A
17:10 17:15 Closing remarks
11¿ù 07ÀÏ (Åä¿äÀÏ)
09:00 10:00 ÆòÀÇ¿øȸ(¿Â¶óÀÎ)
10:00 12:00 Ç÷¿ìº´¿¬±¸È¸
10:00 10:25 Novel agents and current treatment changes in hemophilia : Emicizumab
VOD ´Ù½Ãº¸±â
ÇÑÁ¤¿ì(¿¬¼¼ÀÇ´ë)
10:25 10:50 Novel therapeutics and current treatment changes in hemophilia : Fitusiran, anti-TFPI and gene therapy
VOD ´Ù½Ãº¸±â
¹Ú¿µ½Ç(°æÈñÀÇ´ë)
10:50 10:55 Questions/Answers and Discussion (I)
10:55 11:20 Multidisciplinary clinic and role of the hematologist : Hemostatic support for the management in the multidisciplinary clinics
VOD ´Ù½Ãº¸±â
¹éÈñÁ¶(Àü³²ÀÇ´ë)
11:20 11:45 Recent update on the clinical guideline for hemophilia
VOD ´Ù½Ãº¸±â
ÃÖÀºÁø(´ë±¸°¡Å縯ÀÇ´ë)
11:45 11:50 Questions/answers and discussion
11:50 12:00 ÃÑȸ (¿Â¶óÀÎ)